Related Experiment Video
Updated: Aug 10, 2026
12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Leydig cell tumor after treatment for Ewing's sarcoma
Linda J Butros1, Shaji Phillip, Alexander Chou
1Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
Pediatric Blood & Cancer
|March 10, 2006
Summary
A patient developed a Leydig cell tumor 18 years after Ewing's sarcoma treatment. This rare second cancer highlights the need for long-term monitoring in survivors.
Area of Science:
- Oncology
- Endocrinology
- Cancer Survivorship
Background:
- Leydig cell tumors are rare, comprising 3% of testicular neoplasms.
- Ewing's sarcoma is a rare malignant bone tumor, primarily affecting children and young adults.
- Second malignancies after cancer treatment are an increasing concern in long-term survivors.
Observation:
- A patient with a history of treated Ewing's sarcoma developed a Leydig cell tumor of the testis.
- This represents the first reported case of a Leydig cell tumor following Ewing's sarcoma treatment.
Findings:
- The Leydig cell tumor was diagnosed 18 years post-Ewing's sarcoma treatment.
- This case challenges the previously established understanding of cancer treatment sequelae.
Implications:
- Long-term surveillance for secondary malignancies may be warranted for Ewing's sarcoma survivors.
- Further research is needed to understand the potential link between Ewing's sarcoma treatment and Leydig cell tumor development.
- Improved long-term survival rates for Ewing's sarcoma necessitate comprehensive follow-up strategies.
